國際新聞精選周二（2017年1月3日）

2017年1月4日 | Filed under: | Posted by: 朱貴東

17 Thoughts on Biotech Stocks to Kick Off 2017

Before you invest one single dime in any biotech stock you have got to KNOW WHAT YOU ARE BUYING! Get THE most comprehensive text covering the 186 biotech companies that have gone public since 2013! There’s nothing else like it for digging into this highly speculative group of stocks. 【閱讀全文】

After 2015's bumper crop, 2016's new drug approvals don't measure up

After two of the most bountiful years in nearly two decades, new drug approvals slowed this year, with 2016 notching a disappointing 22 approvals compared to the 45 approved in 2015 and the 41 in 2014. The drop-off doesn’t stem from a lack of applications, though. The FDA received 36 applications for new molecular entities in 2016, on par with the average of 35 per year in the past decade. So what gives?【閱讀全文】

The winners, and losers, in the ugly 2016 race for new drug approvals
We've known for a few months now that 2016 was going to be a disappointing year for new drug approvals. So it was no great surprise that the final tally at the FDA rang up at a meager 22. Last year at this time, though, we were heralding a generation-high score of 45 OKs, and it doesn’t take a math genius to see how bad the drop was.【閱讀全文】

Here's Why Inotek Pharmaceuticals Corp. Is Being Obliterated

Investors in Inotek Pharmaceuticals (NASDAQ:ITEK), a clinical-stage biopharma focused on diseases of the eye, are having a tough start to the new year. Shares are collapsing in early-morning trading on Tuesday, falling more than 68% as of 10:05 a.m EST after the company reported results from a phase 3 study that failed to meet its primary endpoint. 【閱讀全文】

Agile Therapeutics shares plummet after contraceptive study data
Agile Therapeutics Inc. AGRX, -12.28% shares plummeted in the extended session Tuesday even after the women's health company reported positive results in a study of its Twirla contraceptive patch. Agile shares dropped 73% to $1.33 after hours. Using the Pearl index, which is the number of times the contraceptive fails over a calculated 100 years of use, Twirla scored a 4.80 for its target population, but 51.4% of study participants had to discontinue the study. The FDA will have to review how Agile calculated the Pearl index results, the company said. Agile plans to resubmit its marketing application to the FDA in the first half of 2017.【閱讀全文】